Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)
China · Delayed Price · Currency is CNY 8.08
-0.13 (-1.58%)
Aug 14, 2026, 3:00 PM CST
SHA:603707 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 4,034 | 3,991 | 3,924 | 3,931 | 3,713 | 3,687 |
Revenue Growth | 6.04% | 1.71% | -0.20% | 5.89% | 0.71% | 26.48% |
Gross Profit Gross Profit Growth | 1,748 | 1,753 | 1,812 | 659.14 | 1,935 | 2,083 |
Operating Income Operating Income Growth | 714.11 | 718.62 | 963.27 | -332.31 | 1,022 | 1,232 |
Net Income Net Income Growth | 585.83 | 581.54 | 826.14 | -189.45 | 1,091 | 1,059 |
Earnings Per Share EPS Growth | 0.36 | 0.36 | 0.50 | -0.12 | 0.67 | 0.67 |
EPS Growth | -18.38% | -28.00% | - | - | 0% | 31.97% |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
Standard heparin API Standard heparin API Growth | 400.73 |
Pharmaceutical Preparations Pharmaceutical Preparations Growth | 3,516 |
CDMO and Other Products CDMO and Other Products Growth | 68.61 |
Other Other Growth | 5.55 |
Total Total Growth | 3,991 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 3,387 | 2,711 | 2,080 | 1,892 | 1,390 | 918.35 |
Total Debt Total Debt Growth | 2,678 | 2,353 | 2,079 | 2,598 | 2,971 | 2,051 |
Net Cash (Debt) Net Cash Growth | 708.99 | 358.17 | 1.13 | -706.06 | -1,581 | -1,133 |
Net Cash Growth | - | 31507.10% | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 0.43 | 0.22 | 0.00 | -0.45 | -0.97 | -0.72 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 1,529 | 1,183 | 1,501 | 1,619 | 595.45 | 683.63 |
Capital Expenditures CapEx Growth | -389.38 | -560.15 | -506.82 | -419.07 | -470.08 | -440.76 |
Free Cash Flow Free Cash Flow Growth | 1,139 | 622.64 | 994.41 | 1,200 | 125.37 | 242.87 |
Free Cash Flow Growth | 42.64% | -37.39% | -17.14% | 857.27% | -48.38% | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 43.33% | 43.92% | 46.17% | 16.77% | 52.11% | 56.51% |
Operating Margin | 17.70% | 18.01% | 24.55% | -8.45% | 27.51% | 33.41% |
Pretax Margin | 17.46% | 17.53% | 25.28% | -7.50% | 31.93% | 32.65% |
Profit Margin | 14.52% | 14.57% | 21.06% | -4.82% | 29.38% | 28.73% |
FCF Margin | 28.24% | 15.60% | 25.34% | 30.53% | 3.38% | 6.59% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.100 | 0.100 | 0.100 | 0.100 | 0.115 | 0.115 |
Dividend Per Share Growth | 0% | 0% | 0% | -13.04% | -0.35% | 29.95% |
Dividend Yield | 1.24% | 1.12% | 0.77% | 0.69% | 0.66% | 0.37% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 22.58 | 25.09 | 25.95 | - | 26.65 | 49.14 |
Forward PE | 12.63 | 14.80 | 17.95 | 19.44 | 19.56 | 38.80 |
P/FCF Ratio | 11.45 | 23.43 | 21.56 | 20.14 | 231.92 | 214.34 |
PS Ratio | 3.23 | 3.66 | 5.46 | 6.15 | 7.83 | 14.12 |